Home » Topics » Regulatory » EMA

EMA
RSS

Hemophilia A gene therapy from Sangamo and Pfizer receives E.U. orphan drug designation

June 7, 2017

EMA's COMP recommends orphan medicinal product designation for Catalyst Biosciences' CB-2679d

June 1, 2017

Dasiglucagon receives positive opinion for designation as orphan medicinal product

May 30, 2017

EMA grants PRIME designation for asunercept as treatment of glioblastoma

May 30, 2017

Myrcludex B granted EMA PRIME eligibility

May 26, 2017

EMA awards orphan drug designation to Actinium's Actimab-A

May 25, 2017

EMA committee recommends orphan drug designation for MK-0677

May 25, 2017

FDA and EMA accept submissions for UX-003 for mucopolysaccharidosis VII

May 24, 2017

EMA grants orphan drug designation to avacopan for C3 glomerulopathy

May 24, 2017

EMA committee recommends approval of Oxervate for neurotrophic keratitis

May 23, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...